Drug – bio-affecting and body treating compositions – Designated organic active ingredient containing – Having -c- – wherein x is chalcogen – bonded directly to...
Reexamination Certificate
1993-12-21
2002-07-09
Fay, Zohreh (Department: 1614)
Drug, bio-affecting and body treating compositions
Designated organic active ingredient containing
Having -c-, wherein x is chalcogen, bonded directly to...
C514S408000, C514S422000, C514S443000
Reexamination Certificate
active
06417198
ABSTRACT:
BACKGROUND OF THE INVENTION
In climacteric women, anxiety, depression, tension and irritability begin during the perimenopause and can be correlated to reduced estrogen levels and estrogen replacement therapy has been recommended for the treatment of these symptoms (Malleson J.,
Lancet,
2: 158, (1953); Wilson et. al.,
J. Am. Geriatric Soc.,
11: 347 (1963)). The mechanism for protective effects of estrogen in this case is unknown, but may be related to potential effects of estrogen on biogenic amines such as serotonin (Aylward M.,
Int. Res. Communications System Med. Sci.,
1: 30 (1973)). To this regard circulating serotonin is reduced in post-menopausal women (Gonzales G., et. al.,
Maturitas
17: 23-29 (1993)), and serotonin (as well as several other biogenic amines) have a putative role in behavioral depression.
Phillips and Sherwin (
Psychoneuroendocrinology,
17: 485-495 (1992)) reported that in surgically menopausal women given estrogen, scores in immediate and delayed recall tests are greater than in similar women not given estrogen. Two potential hypotheses might explain this effect. There is some evidence that partial estrogen agonists (or anti-estrogens) such as tamoxifen interact with the muscarinic receptor (Ben-Baruch G., et. al.,
Molec. Pharmacol.
21: 287-293 1982), and muscarinic agonists (M
2
) are known to produce positive effects in a number of memory associated tasks and may have clinical relevance in Alzheimer's Disease. Another interesting possibility may be linked to neurokinins such as Substance P, which are known to have neurotrophic as well as memory-promoting effects (Thoenen H.,
Trends in Neuroscience,
14: 165-170 (1991); Huston J. et. al.,
Neurosci. Biobehav. Rev.
13: 171-180 (1989)), thus, through an effect either at a neurotransmitter receptor in the CNS or at a neuropeptide receptor, a tissue selective estrogen agonist/antagonist could produce memory and cognitive enhancing effects. Such an activity would most relevantly be assessed in man, but a variety of animal models (i.e. maze learning, extinction etc.) are available for preclinical testing.
Perhaps the most frequent CNS related problem in climacteric women is the occurrence of hot flushes. While this undoubtedly is a somatic effect mediated by effects on the microvasculature, current evidence points strongly in the direction of CNS initiated effect (Lomax P., et. al.,
Pharmac. Ther.
57: 347-358 (1993)). Therefore, a tissue selective estrogen agonist/antagonist like raloxifene might offer the ideal therapy providing the desired effect in the absence of untoward side effects on reproductive tissue.
SUMMARY OF THE INVENTION
This invention provides methods for inhibiting CNS problems in a post-menopausal female comprising administering to a female human in need of treatment an effective amount of a compound of formula I
wherein R
1
and R
3
are independently hydrogen,
wherein Ar is optionally substituted phenyl;
R
2
is selected from the group consisting of pyrrolidino, hexamethyleneimino, and piperidino; and pharmaceutically acceptable salts and solvates thereof.
REFERENCES:
patent: 4133814 (1979-01-01), Jones et al.
patent: 4380635 (1983-04-01), Peters
patent: 4418068 (1983-11-01), Jones
patent: 4894373 (1990-01-01), Young
patent: 5389670 (1995-02-01), Fontana
patent: 5393763 (1995-02-01), Black et al.
patent: 5434166 (1995-07-01), Glasebrook
patent: 5439931 (1995-08-01), Sales
patent: 5441947 (1995-08-01), Dodge et al.
patent: 5445941 (1995-08-01), Yang
patent: 5462950 (1995-10-01), Fontana
patent: 5464845 (1995-11-01), Black et al.
patent: 5468773 (1995-11-01), Dodge et al.
patent: 5482949 (1996-01-01), Black et al.
patent: 5510370 (1996-04-01), Huck
patent: 5512296 (1996-04-01), Cullinan
patent: 5534526 (1996-07-01), Cullinan
patent: 5550150 (1996-08-01), Fontana
patent: 5552415 (1996-09-01), May
patent: 5567713 (1996-10-01), Cullinan et al.
patent: 5578613 (1996-11-01), Bryant et al.
patent: 5578614 (1996-11-01), Bryant et al.
patent: 4320896 (1993-06-01), None
patent: 0178862 (1986-04-01), None
patent: 1064629 (1967-04-01), None
patent: WO93/10113 (1993-05-01), None
patent: WO93/1074 (1993-06-01), None
“Women on Estrogen Appear at Less Risk of Alzhimer's”,Indianapolis Star,Nov. 10, 1993.
“New Alzheimer's Therapy Suggested”,Science,260, pp. 1719-1720 (Jun. 18, 1993).
Draper et al., “Effects of Raloxifene (LY139481 HC1) on Biochemical Markers of Bone and Lipid Metabolism i Healthy Postmenopausal Women”, Hong Kong, Fourth Int'l Symp. on Osteoporosis, Mar. 29, 1993.
Bryant et al., “Protection from Bone Loss and Lowering of Serum Cholesterol in the Absence of Uterine Stimulation in Ovariectomized Rats”, Am Soc. Bone & Min. Res., Tampa, Sep. 18-22, 1993.
Bryant et al., “Raloxifene is a Tissue Specific Estrogen Agonist”, Am Soc. Bone & Min. Res., Tampa, Sep. 18-22, 1993.
Frolick et al., “In Vivo and In Vitro Metabolism of Raloxifene”, Am. Soc. Bone & Min. Res., Tampa, Sep. 18-22, 1993.
Glasebrook et al., “Multiple Binding Sites for the Anti-estrogen Raloxifene”, Am Soc. Bone & Min. Res., Tampa, Sep. 18-22, 1993.
Hock et al., “Combination of Raloxifene and Human Parathyroid Hormone 1-34; Increased Femur Bone Mass in Young Ovariectomized (OVX) Rats”, Am. Soc. Bone & Min. Res., Tampa, Sep. 18-22, 1993.
Sato et al., “DEXA Analysis of Raloxifene Effects on the Bones From Ovariectomized Rats”, Am. Soc. for Bone and Min. Res., Tampa, Sep 18-22, 1993.
Yang et al., “Raloxifene an Anti-Estrogen, Simulates the Effects of Estrogen in Inhibiting Bone Resorption Through Regulating TGFB-3 Expression in Bone;”.Am Soc. for Bone and Min. Res., Tampa, Sep. 18-22, 1993.
Black et al., “Distinct, Structure-Related Profiles of Estrogenic and Anti-Estrogenic Activity in the Tamoxifen and LY117018 Series;” The Endocrine Society, Abstract 1982.
Black et al., “Uterine Bioassay of Tamoxifen, Trioxifene, and New Estrogen Antagonist (LY117018) in Rats and Mice,” Life Sciences, 26:1980, 1453-1458.
Black et al., “Differential Interaction of Antiestrogens with Cytosol Estrogen Receptors,” Molecular and Cellular Endocrinology, 22:1981, 95-103.
Black et al., “Evidence for Biological Action of the Antiestrogens LY117018 and Tamoxifen by Different Mechanisms,” Endocrinology 109;1981, 987-989.
Black, L.J. “Biological Actions and Binding Properites of a New Estrogen Antagosist LY117018,” In: Homone Antagonists, 129-82, 1982, (M.K. Agarwal ed.) Walter de Gruyter and Co., Berlin New York.
Black et al., LY156758: A Unique Antiestrogen Displaying High Affinity for Estrogen Receptors, Negligible Estrogenic Activity and Near-Total Estrogen Antagonism in Vivo. Presented at the Fifth Annual San Antonio Breast Cancer Symposium, San Antonio, Texas, Nov. 5-6, 1982.
Black et al., The Antiestrogenic Action of LY139481: Species Uniformity Duration of Action and Kinetics of 3H-LY139481 Distribution In Vivo. Sixty-fifth Annual Meeting of the Endocrine Society, San Antonio, Texas, Jun. 8-10, 1983, abs. 93.
Black et al., Antagonism of Estrogen Action with a New benzothiophene Derived Antiestrogen, Life Sciences, 32:1983. 1031-1036.
Black et al., The Relationship of the Antiestrogenic Efficacy of LY156758 to its Pharmacokinetics and Metabolism Following Oral Administration to Adult Ovariectomized Rats, Seventh International Congress of Endocrinology, Quebec City, Canada, Jul. .1-7, 1984, abs. 323.
Black et al., Synthesis and Antiestrogenic Activity of [3,4-Dihydro-2(4-methoxyphenyl)-1-napthalenyl] [4-[2-pyrrolidinyl)ethoxly]-phenyl] methanone, methanesulfonic acid salt, Journal of Medicinal Chemistry 22;1979, 962-966.
Black et al., Antiestrogens 2. Structure Activity Studies in a Series of 3-Aroyl-2-arylbenzo[b]thiophene Derivatives Leading to 6-Hydroxy-2-(4-hydroxyphenyl)benzo [b ] thien-3-yl [4-2-(1-piperidinyl) ethoxy]-phenyl methanone Hydrochloride (LY156758), a Remarkably Effective Estrogen Antagonist with Only Minimal Intrinsic Estrogenicity, J. Med. Chem. 27(8), 1984, 1057-1066.
Bryant Henry U.
Glasebrook Andrew L.
Grese Timothy A.
Phillips David L.
Boudreaux William R.
Eli Lilly and Company
Fay Zohreh
Sales James J.
LandOfFree
Methods of inhibiting CNS problems in post-menopausal women does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Methods of inhibiting CNS problems in post-menopausal women, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Methods of inhibiting CNS problems in post-menopausal women will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-2903688